These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27841717)

  • 1. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
    Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
    J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy.
    Bonifacio M; Maheshwari V; Tran D; Agostoni G; Filioussi K; Viana R
    Pharmacoecon Open; 2022 Jan; 6(1):95-104. PubMed ID: 34297312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].
    Yuan T; Lai YY; Qin YZ; Shi HX; Huang XJ; Hou Y; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):93-99. PubMed ID: 32135623
    [No Abstract]   [Full Text] [Related]  

  • 4. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
    Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
    Smith BD; Brümmendorf TH; Roboz GJ; Gambacorti-Passerini C; Charbonnier A; Viqueira A; Leip E; Purcell S; Goldman EH; Giles F; Ernst T; Hochhaus A; Rosti G
    Leuk Res; 2024 Apr; 139():107481. PubMed ID: 38484432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
    Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia.
    Klink AJ; Keating SJ; Brokars J; Feinberg B; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):149-157. PubMed ID: 38135632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of nilotinib
    Yu L; Qin YZ; Lai YY; Shi HX; Huang XJ; Hou Y; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):996-1002. PubMed ID: 32023729
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.
    Sasaki K; Lahoti A; Jabbour E; Jain P; Pierce S; Borthakur G; Daver N; Kadia T; Pemmaraju N; Ferrajoli A; O'Brien S; Kantarjian H; Cortes J
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):152-62. PubMed ID: 26796981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].
    Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):215-224. PubMed ID: 38716592
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
    Zhang X; Xu N; Yang Y; Lin H; Liu B; Du X; Liu X; Liang R; Chen C; Huang J; Zhu H; Pan L; Wang X; Li G; Liu Z; Zhang Y; Liu Z; Hu J; Liu C; Li F; Yang W; Meng L; Han Y; Lin L; Zhao Z; Tu C; Zheng C; Bai Y; Zhou Z; Chen S; Qiu H; Yang L; Sun X; Sun H; Zhou L; Liu Z; Wang D; Guo J; Pang L; Zeng Q; Suo X; Zhang W; Zheng Y; Zhang Y; Li W; Jiang Q
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):e257-e266. PubMed ID: 38461040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New dosing schedules of dasatinib for CML and adverse event management.
    Wong SF
    J Hematol Oncol; 2009 Feb; 2():10. PubMed ID: 19236716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia.
    Hijiya N; Zwaan CM; Rizzari C; Foà R; Abbink F; Lancaster D; Landman-Parker J; Millot F; Moppett J; Nelken B; Caterina Putti M; Tian X; Sinclair K; Santanastasio H; Buchbinder A; Kearns P
    Clin Cancer Res; 2020 Feb; 26(4):812-820. PubMed ID: 31676669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study.
    Hijiya N; Maschan A; Rizzari C; Shimada H; Dufour C; Goto H; Kang HJ; Guinipero T; Karakas Z; Bautista F; Ducassou S; Yoo KH; Zwaan CM; Millot F; Patterson BC; Samis J; Izquierdo M; Titorenko K; Li S; Sosothikul D
    Blood Adv; 2023 Dec; 7(23):7279-7289. PubMed ID: 37738125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
    Cortes JE; Saglio G; Kantarjian HM; Baccarani M; Mayer J; Boqué C; Shah NP; Chuah C; Casanova L; Bradley-Garelik B; Manos G; Hochhaus A
    J Clin Oncol; 2016 Jul; 34(20):2333-40. PubMed ID: 27217448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The Effect and Safety of Flumatinib in Patients with Chronic Myelogenous Leukemia Failed First-and Second-line Treatment].
    Liu LY; Wei JF; Jia T; Mao JP; Cai ZM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):370-375. PubMed ID: 38660838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia.
    Inoue H; Taji H; Yamada K; Iriyama C; Saito T; Kato H; Yanada M; Yamamoto K; Matsukawa N
    Intern Med; 2020 Oct; 59(19):2419-2421. PubMed ID: 32611965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.
    Atallah E; Mauro MJ; Hochhaus A; Boquimpani C; Minami Y; Maheshwari VK; Saini L; Corbin R; Réa D
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6247-6262. PubMed ID: 36707445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.
    Shin J; Koh Y; Yoon SH; Cho JY; Kim DY; Lee KH; Kim HJ; Ahn JS; Kim YK; Park J; Sohn SK; Moon JH; Lee YJ; Yoon S; Lee JO; Cheong JW; Kim KH; Kim SH; Kim HG; Kim H; Nam SH; Do YR; Park SG; Park SK; Bae SH; Song HH; Shin DY; Oh D; Kim MK; Jung CW; Park S; Kim I
    Cancer Med; 2018 May; 7(5):1814-1823. PubMed ID: 29577674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia.
    Ureshino H; Kamachi K; Kimura S
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e138-e141. PubMed ID: 38195325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.